The liver cancer diagnostics market size has grown strongly in recent years. It will grow from $10.32 billion in 2025 to $11.07 billion in 2026 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to increasing prevalence of chronic liver diseases, rising incidence of hepatocellular carcinoma, expansion of hospital diagnostic infrastructure, growing awareness of early cancer screening, advancements in imaging and pathology techniques.
The liver cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to $14.75 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to increasing adoption of precision oncology diagnostics, rising demand for non-invasive diagnostic methods, expansion of molecular testing capabilities, growing investments in oncology research, increasing use of ai-assisted diagnostic platforms. Major trends in the forecast period include increasing adoption of advanced molecular diagnostic tests, rising use of imaging-based early detection tools, growing integration of biomarker-based screening methods, expansion of personalized oncology diagnostics, enhanced focus on early-stage cancer detection.
The anticipated rise in the prevalence of liver cancer is set to drive the growth of the liver cancer diagnostics market. Liver cancer, characterized by the uncontrolled growth of liver cells, poses a severe health risk. Diagnostic tests for liver cancer play a crucial role in determining the extent of cancer cell spread within or around the liver following the diagnosis of primary liver carcinoma. A report from the American Cancer Society revealed an increase in new cases of liver and intrahepatic bile duct cancer among females, reaching 13,230 in 2023 in the United States. The total estimated new cases of liver cancer for 2023 in the US are 41,210, with an expected 29,380 fatalities. This underscores the pressing need for liver cancer diagnostics due to the escalating prevalence of the disease.
Key companies in the liver cancer diagnostics market are creating advanced biomarker-based assays and algorithms to enhance diagnostic accuracy and facilitate early detection. Biomarker-based assays and algorithms are diagnostic tools that employ specific biological markers to identify diseases, offering more precise and efficient diagnostic capabilities. For example, in November 2023, Roche Diagnostics, a U.S.-based biotech corporation, introduced the Elecsys PIVKA-II assay and the Elecsys GAAD algorithm. The Elecsys PIVKA-II assay identifies elevated levels of the PIVKA-II biomarker, which is linked to hepatocellular carcinoma (HCC), thereby improving early liver cancer detection in high-risk patients. Meanwhile, the Elecsys GAAD algorithm combines various diagnostic markers, including PIVKA-II and AFP, to enhance diagnostic accuracy and streamline decision-making in liver cancer detection.
In December 2024, Metropolis Healthcare Limited, an India-based healthcare diagnostics company, acquired Core Diagnostics for USD 0.0278 billion. Through this acquisition, Metropolis aims to substantially strengthen its advanced cancer testing capabilities and broaden its footprint across northern and eastern India, reinforcing its position in the specialized diagnostics segment. Core Diagnostics Private Limited is an India-based specialty diagnostics company that offers advanced testing solutions focused on liver cancer diagnostics.
Major companies operating in the liver cancer diagnostics market are Abbott Laboratories, F Hoffmann La Roche Ltd, Qiagen NV, Thermo Fisher Scientific Inc, Siemens Healthineers, Illumina Inc, Koninklijke Philips NV, Epigenomics AG, Digna Biotech SL, Biocept Inc, Danaher Corporation, Foundation Medicine Inc, Agilent Technologies Inc, Genemed Biotechnologies Inc, Merck KGaA, Fujifilm Medical Systems USA Inc, GE Healthcare, Advanced Cell Diagnostics Inc, Oxford Gene Technology, Leica Biosystems Nussloch GmbH, Exiqon AS, BioGenex Laboratories Inc, OncoCyte Corporation, Guardant Health Inc, Exact Sciences Corporation, Grail Inc, Freenome Holdings Inc, Natera Inc, Personal Genome Diagnostics Inc, Thrive Earlier Detection Corp.
North America was the largest region in the liver cancer diagnostics market in 2025. The regions covered in the liver cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the liver cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the liver cancer diagnostics market by increasing costs of imported imaging systems, laboratory analyzers, reagents, molecular testing kits, and diagnostic consumables used across hospitals and diagnostic laboratories. North America and Europe are most affected due to reliance on advanced imported diagnostic equipment, while Asia-Pacific faces cost pressures on reagents and imaging device imports. These tariffs are raising diagnostic procedure costs and slowing equipment upgrades. However, they are also encouraging domestic manufacturing of diagnostic kits, regional reagent production, and localized development of imaging and molecular diagnostic technologies.
The liver cancer diagnostics market research report is one of a series of new reports that provides liver cancer diagnostics market statistics, including liver cancer diagnostics industry global market size, regional shares, competitors with a liver cancer diagnostics market share, detailed liver cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the liver cancer diagnostics industry. This liver cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Liver cancer diagnostics encompass a range of techniques utilized for the identification and assessment of liver cancer, a malignancy originating in the liver. These methods play a crucial role in the early detection and diagnosis of liver cancer, utilizing both imaging and molecular testing.
Hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, and other related forms constitute the primary types of cancer addressed in liver cancer diagnostics. Hepatocellular carcinoma (HCC) specifically pertains to the predominant liver cancer affecting individuals with cirrhosis and preexisting chronic liver disease. The screening process involves various approaches such as laboratory testing, imaging, endoscopy, biopsy, and others. Diverse technologies, including fluorescent in situ hybridization (FISH), comparative genomic hybridization (CGH), immunohistochemical (IHC), among others, are employed across different end uses, including hospitals and diagnostic laboratories, academic and research institutes, and pharmaceutical and CRO laboratories.
The liver cancer diagnostics market includes revenues earned by entities by liver transplants, CT scans, and liver function tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The liver cancer diagnostics market also includes sales of In Vitro and Imaging Tools, AI tools, and ML tools which are used in providing liver cancer diagnostic services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The liver cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to $14.75 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to increasing adoption of precision oncology diagnostics, rising demand for non-invasive diagnostic methods, expansion of molecular testing capabilities, growing investments in oncology research, increasing use of ai-assisted diagnostic platforms. Major trends in the forecast period include increasing adoption of advanced molecular diagnostic tests, rising use of imaging-based early detection tools, growing integration of biomarker-based screening methods, expansion of personalized oncology diagnostics, enhanced focus on early-stage cancer detection.
The anticipated rise in the prevalence of liver cancer is set to drive the growth of the liver cancer diagnostics market. Liver cancer, characterized by the uncontrolled growth of liver cells, poses a severe health risk. Diagnostic tests for liver cancer play a crucial role in determining the extent of cancer cell spread within or around the liver following the diagnosis of primary liver carcinoma. A report from the American Cancer Society revealed an increase in new cases of liver and intrahepatic bile duct cancer among females, reaching 13,230 in 2023 in the United States. The total estimated new cases of liver cancer for 2023 in the US are 41,210, with an expected 29,380 fatalities. This underscores the pressing need for liver cancer diagnostics due to the escalating prevalence of the disease.
Key companies in the liver cancer diagnostics market are creating advanced biomarker-based assays and algorithms to enhance diagnostic accuracy and facilitate early detection. Biomarker-based assays and algorithms are diagnostic tools that employ specific biological markers to identify diseases, offering more precise and efficient diagnostic capabilities. For example, in November 2023, Roche Diagnostics, a U.S.-based biotech corporation, introduced the Elecsys PIVKA-II assay and the Elecsys GAAD algorithm. The Elecsys PIVKA-II assay identifies elevated levels of the PIVKA-II biomarker, which is linked to hepatocellular carcinoma (HCC), thereby improving early liver cancer detection in high-risk patients. Meanwhile, the Elecsys GAAD algorithm combines various diagnostic markers, including PIVKA-II and AFP, to enhance diagnostic accuracy and streamline decision-making in liver cancer detection.
In December 2024, Metropolis Healthcare Limited, an India-based healthcare diagnostics company, acquired Core Diagnostics for USD 0.0278 billion. Through this acquisition, Metropolis aims to substantially strengthen its advanced cancer testing capabilities and broaden its footprint across northern and eastern India, reinforcing its position in the specialized diagnostics segment. Core Diagnostics Private Limited is an India-based specialty diagnostics company that offers advanced testing solutions focused on liver cancer diagnostics.
Major companies operating in the liver cancer diagnostics market are Abbott Laboratories, F Hoffmann La Roche Ltd, Qiagen NV, Thermo Fisher Scientific Inc, Siemens Healthineers, Illumina Inc, Koninklijke Philips NV, Epigenomics AG, Digna Biotech SL, Biocept Inc, Danaher Corporation, Foundation Medicine Inc, Agilent Technologies Inc, Genemed Biotechnologies Inc, Merck KGaA, Fujifilm Medical Systems USA Inc, GE Healthcare, Advanced Cell Diagnostics Inc, Oxford Gene Technology, Leica Biosystems Nussloch GmbH, Exiqon AS, BioGenex Laboratories Inc, OncoCyte Corporation, Guardant Health Inc, Exact Sciences Corporation, Grail Inc, Freenome Holdings Inc, Natera Inc, Personal Genome Diagnostics Inc, Thrive Earlier Detection Corp.
North America was the largest region in the liver cancer diagnostics market in 2025. The regions covered in the liver cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the liver cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the liver cancer diagnostics market by increasing costs of imported imaging systems, laboratory analyzers, reagents, molecular testing kits, and diagnostic consumables used across hospitals and diagnostic laboratories. North America and Europe are most affected due to reliance on advanced imported diagnostic equipment, while Asia-Pacific faces cost pressures on reagents and imaging device imports. These tariffs are raising diagnostic procedure costs and slowing equipment upgrades. However, they are also encouraging domestic manufacturing of diagnostic kits, regional reagent production, and localized development of imaging and molecular diagnostic technologies.
The liver cancer diagnostics market research report is one of a series of new reports that provides liver cancer diagnostics market statistics, including liver cancer diagnostics industry global market size, regional shares, competitors with a liver cancer diagnostics market share, detailed liver cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the liver cancer diagnostics industry. This liver cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Liver cancer diagnostics encompass a range of techniques utilized for the identification and assessment of liver cancer, a malignancy originating in the liver. These methods play a crucial role in the early detection and diagnosis of liver cancer, utilizing both imaging and molecular testing.
Hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, and other related forms constitute the primary types of cancer addressed in liver cancer diagnostics. Hepatocellular carcinoma (HCC) specifically pertains to the predominant liver cancer affecting individuals with cirrhosis and preexisting chronic liver disease. The screening process involves various approaches such as laboratory testing, imaging, endoscopy, biopsy, and others. Diverse technologies, including fluorescent in situ hybridization (FISH), comparative genomic hybridization (CGH), immunohistochemical (IHC), among others, are employed across different end uses, including hospitals and diagnostic laboratories, academic and research institutes, and pharmaceutical and CRO laboratories.
The liver cancer diagnostics market includes revenues earned by entities by liver transplants, CT scans, and liver function tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The liver cancer diagnostics market also includes sales of In Vitro and Imaging Tools, AI tools, and ML tools which are used in providing liver cancer diagnostic services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Liver Cancer Diagnostics Market Characteristics
3. Liver Cancer Diagnostics Market Supply Chain Analysis
4. Global Liver Cancer Diagnostics Market Trends and Strategies
5. Liver Cancer Diagnostics Market Analysis of End Use Industries
7. Global Liver Cancer Diagnostics Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Liver Cancer Diagnostics Total Addressable Market (TAM) Analysis for the Market
9. Liver Cancer Diagnostics Market Segmentation
10. Liver Cancer Diagnostics Market Regional and Country Analysis
11. Asia-Pacific Liver Cancer Diagnostics Market
12. China Liver Cancer Diagnostics Market
13. India Liver Cancer Diagnostics Market
14. Japan Liver Cancer Diagnostics Market
15. Australia Liver Cancer Diagnostics Market
16. Indonesia Liver Cancer Diagnostics Market
17. South Korea Liver Cancer Diagnostics Market
18. Taiwan Liver Cancer Diagnostics Market
19. South East Asia Liver Cancer Diagnostics Market
20. Western Europe Liver Cancer Diagnostics Market
21. UK Liver Cancer Diagnostics Market
22. Germany Liver Cancer Diagnostics Market
23. France Liver Cancer Diagnostics Market
24. Italy Liver Cancer Diagnostics Market
25. Spain Liver Cancer Diagnostics Market
26. Eastern Europe Liver Cancer Diagnostics Market
27. Russia Liver Cancer Diagnostics Market
28. North America Liver Cancer Diagnostics Market
29. USA Liver Cancer Diagnostics Market
30. Canada Liver Cancer Diagnostics Market
31. South America Liver Cancer Diagnostics Market
32. Brazil Liver Cancer Diagnostics Market
33. Middle East Liver Cancer Diagnostics Market
34. Africa Liver Cancer Diagnostics Market
36. Liver Cancer Diagnostics Market Competitive Landscape and Company Profiles
37. Liver Cancer Diagnostics Market Other Major and Innovative Companies
40. Liver Cancer Diagnostics Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Liver Cancer Diagnostics Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses liver cancer diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for liver cancer diagnostics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The liver cancer diagnostics market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Hepatocellular Carcinoma; Cholangiocarcinoma; Hepatoblastoma2) By Screening: Laboratory Testing; Imaging; Biopsy; Other Screenings
3) By Technology: Fluorescent In Situ Hybridization (FISH); Immunohistochemical (IHC); Other Technologies
4) By End Use: Hospitals And Diagnostic Laboratories; Academic And Research Institutes
Subsegments:
1) By Hepatocellular Carcinoma: Early-Stage Hepatocellular Carcinoma; Advanced-Stage Hepatocellular Carcinoma2) By Cholangiocarcinoma: Intrahepatic Cholangiocarcinoma; Extrahepatic Cholangiocarcinoma
3) By Hepatoblastoma: Pure Hepatoblastoma; Mixed Hepatoblastoma
Companies Mentioned: Abbott Laboratories; F Hoffmann La Roche Ltd; Qiagen NV; Thermo Fisher Scientific Inc; Siemens Healthineers; Illumina Inc; Koninklijke Philips NV; Epigenomics AG; Digna Biotech SL; Biocept Inc; Danaher Corporation; Foundation Medicine Inc; Agilent Technologies Inc; Genemed Biotechnologies Inc; Merck KGaA; Fujifilm Medical Systems USA Inc; GE Healthcare; Advanced Cell Diagnostics Inc; Oxford Gene Technology; Leica Biosystems Nussloch GmbH; Exiqon AS; BioGenex Laboratories Inc; OncoCyte Corporation; Guardant Health Inc; Exact Sciences Corporation; Grail Inc; Freenome Holdings Inc; Natera Inc; Personal Genome Diagnostics Inc; Thrive Earlier Detection Corp
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Liver Cancer Diagnostics market report include:- Abbott Laboratories
- F Hoffmann La Roche Ltd
- Qiagen NV
- Thermo Fisher Scientific Inc
- Siemens Healthineers
- Illumina Inc
- Koninklijke Philips NV
- Epigenomics AG
- Digna Biotech SL
- Biocept Inc
- Danaher Corporation
- Foundation Medicine Inc
- Agilent Technologies Inc
- Genemed Biotechnologies Inc
- Merck KGaA
- Fujifilm Medical Systems USA Inc
- GE Healthcare
- Advanced Cell Diagnostics Inc
- Oxford Gene Technology
- Leica Biosystems Nussloch GmbH
- Exiqon AS
- BioGenex Laboratories Inc
- OncoCyte Corporation
- Guardant Health Inc
- Exact Sciences Corporation
- Grail Inc
- Freenome Holdings Inc
- Natera Inc
- Personal Genome Diagnostics Inc
- Thrive Earlier Detection Corp
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 11.07 Billion |
| Forecasted Market Value ( USD | $ 14.75 Billion |
| Compound Annual Growth Rate | 7.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 31 |
